Telix Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
In an exciting announcement, Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX) is set to showcase its innovative work during a significant healthcare event this week. Dr. Christian Behrenbruch, the Managing Director and Group CEO, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference. This highly anticipated event will take place in San Francisco, where industry leaders gather to discuss advancements in healthcare.
Details of the Presentation
The presentation is slated for Wednesday, January 15, at 2:15 PM Pacific Standard Time. Attendees can expect insights into Telix's cutting-edge developments in therapeutic and diagnostic radiopharmaceuticals, a focus area for the company that aims to address medical needs with innovative solutions.
Webcast Availability
For those unable to attend in person, a webcast of the presentation will be available. This ensures that a broader audience can access critical updates on Telix's strategies and product developments. The webcast will be accessible on demand through the company’s website once the event concludes, allowing for continuous engagement with stakeholders and interested parties.
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is a biopharmaceutical company dedicated to developing and commercializing radiopharmaceuticals and associated technologies aimed at improving patient care. Headquartered in Melbourne, Australia, Telix has established a global presence that encompasses operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan.
The Company’s Mission
The core mission of Telix is to serve patients with significant unmet medical needs, particularly in oncology and rare diseases. The company is currently advancing a diverse portfolio of clinical and commercial-stage products. By deploying advanced technology in therapeutic areas, Telix is committed to transforming healthcare outcomes.
Connect with Telix for More Information
For those interested in learning more about Telix Pharmaceuticals, including detailed information on the latest developments and financial performance, the company invites you to visit its website. There, investors and interested stakeholders can find resources including the latest share price, filings, and news releases. The company also maintains an active presence on social media platforms like X and LinkedIn, providing updates and engaging with the community.
Investor Relations Contacts
For investors looking to reach out, Telix provides dedicated contact points. In Australia, Ms. Kyahn Williamson, the Senior Vice President of Investor Relations and Corporate Communications, is available for queries. Residents in the United States can contact Lisa Wilson from In-Site Communications for assistance.
Frequently Asked Questions
What is the focus of Telix Pharmaceuticals?
Telix Pharmaceuticals focuses on developing and commercializing diagnostic and therapeutic radiopharmaceuticals aimed at improving health outcomes in oncology and rare diseases.
Where will the J.P. Morgan Healthcare Conference be held this year?
The 43rd Annual J.P. Morgan Healthcare Conference takes place in San Francisco.
How can I access the webcast of Telix's presentation?
The webcast of Telix's presentation will be accessible on demand via the company’s official website following the conference.
Who is presenting on behalf of Telix Pharmaceuticals?
Dr. Christian Behrenbruch, the Managing Director and Group CEO, will represent Telix Pharmaceuticals at the conference.
How can I find information about Telix's investor relations?
Information can be found on Telix's official website, which includes contact details for investor relations and the latest updates on the company's performance.
